AGPS (alkylglycerone phosphate synthase) is a key enzyme in ether lipid biosynthesis that catalyzes the formation of alkyl-dihydroxyacetonephosphate, the first ether-linked intermediate in this pathway 1. The enzyme is localized to peroxisomes and functions as the rate-limiting step in ether lipid synthesis 1. AGPS activity is tightly regulated through multiple mechanisms, including peroxisomal localization control and protein degradation pathways. Mechanistically, AGPS can be ubiquitinated and degraded by the E3 ligase MDM2, with this process enhanced by TrkA kinase phosphorylation at the Y451 site 2. The enzyme's expression and activity have significant disease relevance, particularly in cancer biology. AGPS promotes ferroptosis susceptibility in both prostate and gastric cancers by modulating ether lipid metabolism 23. In gastric cancer, Helicobacter pylori CagA increases AGPS expression through the MEK/ERK/SRF pathway, making cells more sensitive to ferroptosis and certain therapeutics like apatinib 3. Clinically, AGPS shows promise as both a prognostic biomarker and therapeutic target, with its expression levels correlating with patient survival and treatment response in various cancers 24.